甲氯松 | 4732-48-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 中文名称: 甲氯松
• 英文名称: meclorisone
• 英文别名: 9α,11β-dichloro-16α-methyl-1,4-pregnadiene-17α,21-diol-3,20-dione；(8S,9R,10S,11S,13S,14S,16R,17R)-9,11-dichloro-17-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
• CAS: 4732-48-3
• 化学式: C₂₂H₂₈Cl₂O₄
• 分子量: 427.368
• InChiKey: OKWSMPYQIYKVDC-CXSFZGCWSA-N

物化性质

• 熔点：
  224-227 °C
• 沸点：
  588.0±50.0 °C(Predicted)
• 密度：
  1.35±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  28
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.73
• 拓扑面积：
  74.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  甲氯松 在 过碘酸 作用下， 以 甲醇 、 乙醚 为溶剂， 生成 (8S,9R,10S,11S,13S,14S,16R,17R)-9,11-Dichloro-17-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthrene-17-carboxylic acid methyl ester
  参考文献：
  名称：

  Androstane-17beta-carboxylic acids and processes for the preparation thereof

  摘要：

  公开号：

  US03828080A1
• 作为产物：
  描述：

  1-((3R,8S,9R,10S,11S,13S,14S,16R,17R)-9,11-Dichloro-3,17-dihydroxy-10,13,16-trimethyl-4,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-hydroxy-ethanone 生成 甲氯松
  参考文献：
  名称：

  3β-hydroxy-1,5-bisdehydro steroids

  摘要：

  DOI：

  10.1016/0039-128x(66)90044-4

文献信息

• [EN] COMPOSITIONS FOR USE IN TREATING PULMONARY ARTERIAL HYPERTENSION<br/>[FR] COMPOSITIONS UTILISÉES POUR TRAITER L'HYPERTENSION ARTÉRIELLE PULMONAIRE
  申请人：PELOTON THERAPEUTICS INC

  公开号：WO2016145032A1

  公开（公告）日：2016-09-15

  The present disclosure provides methods of treating pulmonary arterial hypertension (PAH) in a subject in need thereof. Compositions for use in these methods are also provided.

  本公开提供了治疗需要的受试者肺动脉高压（PAH）的方法。还提供了用于这些方法的组合物。
• COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES
  申请人：Johansen Lisa M.

  公开号：US20100009970A1

  公开（公告）日：2010-01-14

  The present invention features compositions, methods, and kits useful in the treatment of viral diseases. In certain embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particular embodiments, the viral disease is viral hepatitis (e.g., hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E) and the agent or combination of agents includes sertraline, a sertraline analog, UK-416244, or a UK-416244 analog. Also featured are screening methods for identification of novel compounds that may be used to treat a viral disease.

  本发明涉及用于治疗病毒性疾病的组合物、方法和试剂盒。在某些实施方式中，病毒性疾病是由单链RNA病毒、黄病毒科病毒或肝病毒引起的。在特定实施方式中，病毒性疾病是病毒性肝炎（例如甲型肝炎、乙型肝炎、丙型肝炎、丁型肝炎、戊型肝炎），药剂或药剂组合包括舍曲林、舍曲林类似物、UK-416244或UK-416244类似物。还包括用于鉴定可用于治疗病毒性疾病的新化合物的筛选方法。
• Synthesis and structure-activity studies of corticosteroid 17-heterocyclic aromatic esters. 1. 9.alpha.,11.beta.-Dichloro series
  作者：Elliot L. Shapiro、Margaret J. Gentles、Robert L. Tiberi、Thomas L. Popper、Joseph Berkenkopf、Barry Lutsky、Arthur S. Watnick

  DOI：10.1021/jm00389a017

  日期：1987.6

  17-hydroxy delta 9(11) compound was acylated at 17, followed by C-ring chlorination. The most extensively studied heterocyclic acyl functionality was the 2-furoyl, but the 3-furoyl, and 2- and 3-thenoyl derivatives were also investigated. Antiinflammatory potencies were measured in mice by a 5-day modification of the Tonelli croton oil ear assay. The most potent topical antiinflammatory compounds were 17-heteroaryl

  描述了一系列9α，11β-二氯-16-甲基皮质类固醇17-杂芳基羧酸盐的制备和局部抗炎作用。在4-（二甲基氨基）吡啶存在下，通过用适当的杂芳基羰基氯直接酰化将17-酰基引入9α，11β-二氯21-乙酸酯中。或者，将21-官能化的17-羟基δ9（11）化合物在17酰化，然后进行C-环氯化。研究最广泛的杂环酰基官能团是2-糠酰基，但是还研究了3-糠酰基以及2-和3-壬酰基衍生物。通过对Tonelli巴豆油耳测定法进行5天修改，测量了小鼠的抗炎能力。最有效的局部抗炎化合物是16个α-甲基系列中的17个杂芳基酯，其中21个取代基是氯或氟。因此，2p [21-氯17-（2'-糠酸酯）]的效力是戊酸倍他米松的8倍，而2s [21-氟17-（2'-糠酸酯）]，2r [21-氯17-（2'-糠酸酯）]，2r [21-氯17-（2'-糠酸酯）]。 -theonate）]和2v [6α-氟21-氯17-（2'
• Pharmaceutical preparation comprising an active dispersed on a matrix
  申请人：——

  公开号：US20040058896A1

  公开（公告）日：2004-03-25

  The present invention relates to the field of pharmaceutical technology and describes a novel advantageous preparation for an active ingredient. The novel preparation is suitable for producing a large number of pharmaceutical dosage forms. In the new preparation an active ingredient is present essentially uniformly dispersed in an excipient matrix composed of one or more excipients selected from the group of fatty alcohol, triglyceride, partial glyceride and fatty acid ester.

  本发明涉及制药技术领域，描述了一种新的有利的活性成分制备方法。这种新的制备方法适用于生产大量的药物剂型。在这种新的制备方法中，活性成分基本上均匀地分散在由脂肪醇、甘油三酯、部分甘油酯和脂肪酸酯等多种赋形剂中选择的一种或多种赋形剂组成的赋形剂基质中。
• Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
  申请人：Scaramuzzino, Giovanni

  公开号：EP1336602A1

  公开（公告）日：2003-08-20

  New pharmaceutical compounds of general formula (I): F-(X)q where q is an integer from 1 to 5, preferably 1; -F is chosen among drugs described in the text, -X is chosen among 4 groups -M, -T, -V and -Y as described in the text. The compounds of general formula (I) are nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without hypotensive side effects and for this reason they are useful for the preparation of medicines for prevention and treatment of inflammatory, ischemic, degenerative and proliferative diseases of musculoskeletal, tegumental, respiratory, gastrointestinal, genito-urinary and central nervous systems.

  通式（I）的新药物化合物：F-（X）q，其中q是1到5的整数，最好是1；-F是在文本中描述的药物中选择的，-X是在文本中描述的4个组-M，-T，-V和-Y中选择的。通式（I）的化合物是硝酸盐前药，可以在体内以受控和选择性的方式释放一氧化氮，而不会产生降压副作用，因此它们非常适用于制备用于预防和治疗肌肉骨骼，皮肤，呼吸，消化，泌尿和中枢神经系统的炎症，缺血，退行性和增生性疾病的药物。